Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

• Published in: Journal of hematology and oncology Vol. 15; no. 1; pp. 1 - 153
• Main Authors: Zhao, Binghao, Li, Huanzhang, Xia, Yu, Wang, Yaning, Wang, Yuekun, Shi, Yixin, Xing, Hao, Qu, Tian, Wang, Yu, Ma, Wenbin
• Format: Journal Article
• Language: English
• Published: London BioMed Central 25-10-2022; BMC
• Subjects: Antitumor activity; B7-H3; Biomarker; Cancer; Cancer immune checkpoints; Cancer immunotherapy; Cell activation; Clinical trials; Crystal structure; Flow cytometry; Glycoproteins; Hematology; Immune checkpoint; Immunology; Immunoregulation; Immunotherapy; Kinases; Lymphocytes; Lymphocytes T; Medical research; Monoclonal antibodies; Neutrophils; Oncology; Proteins; Review; Tumor microenvironment; Tumorigenesis; Tumors
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-022-01364-7

Abstract
Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients.